YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS) 64th Annual Meeting in Atlanta, Georgia, October 5-6, 2018, and the American Academy Of Otolaryngology-Head and Neck Surgery Annual Meeting in Atlanta, Georgia, October 7-10, 2018. Abstracts are available on the ARS Annual Meeting and AAO-HNSF Annual Meeting websites. XHANCE® (fluticasone propionate) nasal spray, 93 mcg, is approved by the U.S. Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age or older.
Data on XHANCE, also referred to as the Exhalation Delivery System with fluticasone (EDS-FLU), is expected to be highlighted in three podium presentations and one scientific poster presented during the ARS Annual Meeting:
Podium Presentation #2564 – EDS-FLU Improves Sense Of Smell In Patients With Chronic Rhinosinusitis With Nasal Polyps is scheduled on Saturday, October 6; 10:55 a.m. to 11:02 a.m., in Breakout Room 2; Chastain H, I, J, 6th.
Podium Presentation #2569 – Nasal And Sinus Deposition In DRAF-II Post-surgical Anatomy With Drug Delivery By Exhalation Delivery System (EDS) Versus Standard Nasal Spray And Irrigation is scheduled on Saturday, October 6; 11:09 a.m. to 11:16 a.m., in Breakout Room 2; Chastain H, I, J, 6th.
Podium Presentation #2572 – EDS-FLU Improves SNOT-22 Across All Subscales In Patients With Nasal Polyps (Category: Clinical Rhinology) is scheduled on Saturday, October 6; 11:16 a.m. to 11:23 a.m., in Breakout Room 2; Chastain H, I, J, 6th.
Poster Presentation #114 – Association Between SNOT-22, RSDI, And Work Productivity In Chronic Rhinosinusitis With Nasal Polyposis: Analysis Of A Pooled Population Of Patients Treated With The Exhalation Delivery System With Fluticasone (EDS-FLU) is scheduled on Friday, October 5; 6:00 p.m. to 8:00 p.m. in the Augusta Conference Center, Rooms 1-3.
XHANCE data is expected to be highlighted in one podium presentation during the AAO-HNSF Annual Meeting:
Podium Presentation – SNOT-22 Predicts SF-6D-R2 in Medically Treated Patients with Nasal Polyps is scheduled on Sunday, October 7; 4:21 p.m. to 4:26 p.m., in Georgia World Congress Center, Building A, Room 316.
These presentations are intended for scientific discussion only.
Please see the full Prescribing Information at www.XHANCE.com.
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact